UPCOMING EVENT
Nov. 11, 2020
Conference call
Conference call
Now more than ever, each life is unique.
We are proud to lead the efforts for the development of an immunoglobulin against COVID-19 → read more
Our proprietary platform technology and know-how allow us to extract and purify injectable protein therapeutics from human plasma.
The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions.
This video illustrates the mechanism of action of AAT, and its possible therapeutic effects.
Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
The allogeneic transplantation of hematopoietic cells (HCT) is a well-established treatment for hematologic diseases that cannot be cured with conventional treatments.The most common life-threatening complication is Graft Versus Host Disease (GVHD).